Logo image of MIRA

MIRA PHARMACEUTICALS INC (MIRA) Stock Fundamental Analysis

USA - NASDAQ:MIRA - US60458C1045 - Common Stock

1.45 USD
-0.21 (-12.65%)
Last: 9/12/2025, 8:00:01 PM
1.48 USD
+0.03 (+2.07%)
After Hours: 9/12/2025, 8:00:01 PM
Fundamental Rating

2

Overall MIRA gets a fundamental rating of 2 out of 10. We evaluated MIRA against 195 industry peers in the Pharmaceuticals industry. The financial health of MIRA is average, but there are quite some concerns on its profitability. MIRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MIRA had negative earnings in the past year.
MIRA had a negative operating cash flow in the past year.
In the past 5 years MIRA always reported negative net income.
In the past 5 years MIRA always reported negative operating cash flow.
MIRA Yearly Net Income VS EBIT VS OCF VS FCFMIRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

MIRA's Return On Assets of -894.29% is on the low side compared to the rest of the industry. MIRA is outperformed by 95.92% of its industry peers.
Looking at the Return On Equity, with a value of -1362.54%, MIRA is doing worse than 80.10% of the companies in the same industry.
Industry RankSector Rank
ROA -894.29%
ROE -1362.54%
ROIC N/A
ROA(3y)-444.7%
ROA(5y)-340.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRA Yearly ROA, ROE, ROICMIRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

MIRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRA Yearly Profit, Operating, Gross MarginsMIRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for MIRA has been increased compared to 1 year ago.
MIRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MIRA Yearly Shares OutstandingMIRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
MIRA Yearly Total Debt VS Total AssetsMIRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

Based on the Altman-Z score of -25.93, we must say that MIRA is in the distress zone and has some risk of bankruptcy.
MIRA's Altman-Z score of -25.93 is on the low side compared to the rest of the industry. MIRA is outperformed by 83.67% of its industry peers.
There is no outstanding debt for MIRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.93
ROIC/WACCN/A
WACCN/A
MIRA Yearly LT Debt VS Equity VS FCFMIRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

2.3 Liquidity

MIRA has a Current Ratio of 2.79. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.79, MIRA is in line with its industry, outperforming 53.57% of the companies in the same industry.
MIRA has a Quick Ratio of 2.79. This indicates that MIRA is financially healthy and has no problem in meeting its short term obligations.
MIRA has a Quick ratio (2.79) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.79
MIRA Yearly Current Assets VS Current LiabilitesMIRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

MIRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.15%, which is quite impressive.
EPS 1Y (TTM)44.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.73% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.42%
EPS Next 2Y16.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MIRA Yearly EPS VS EstimatesMIRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRA. In the last year negative earnings were reported.
Also next year MIRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRA Price Earnings VS Forward Price EarningsMIRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRA Per share dataMIRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

MIRA's earnings are expected to grow with 16.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MIRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIRA PHARMACEUTICALS INC

NASDAQ:MIRA (9/12/2025, 8:00:01 PM)

After market: 1.48 +0.03 (+2.07%)

1.45

-0.21 (-12.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners5.81%
Inst Owner Change3.26%
Ins Owners4.66%
Ins Owner Change4.39%
Market Cap27.65M
Analysts82.86
Price Target18.11 (1148.97%)
Short Float %1.78%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.88%
Min EPS beat(2)25.63%
Max EPS beat(2)32.13%
EPS beat(4)4
Avg EPS beat(4)26.66%
Min EPS beat(4)11.45%
Max EPS beat(4)37.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)23.48%
PT rev (3m)23.48%
EPS NQ rev (1m)-11.76%
EPS NQ rev (3m)26.92%
EPS NY rev (1m)3.9%
EPS NY rev (3m)15.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 48.53
P/tB 48.53
EV/EBITDA N/A
EPS(TTM)-0.49
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -894.29%
ROE -1362.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-444.7%
ROA(5y)-340.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.79
Altman-Z -25.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y27.42%
EPS Next 2Y16.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.69%
OCF growth 3YN/A
OCF growth 5YN/A